Richard Jaenisch and Christopher Cole discuss AI in pharma manufacturing, covering learning steps, output evaluation, hallucinations, and FDA/EMA guiding principles.

This week, PharmTech took a look at the shift toward proactive, data-driven contamination control, the adoption of advanced material science to solve manufacturing hurdles, and an ...

New PRAC safety data link cenobamate to rare severe liver injury, prompting updated monitoring requirements and revised ...

Christopher Lewis, Emoja Biopharma, explores how AI can streamline compliance, cut investigation time, and free skilled ...

Legacy web forms used for clinical trial recruitment, adverse event reporting, laboratory data collection, and regulatory ...

Digital twins function as synchronized, real-time operational mirrors, where divergence from the physical process triggers ...

On April 9, 2026, Oxford BioTherapeutics announced a multi-year collaboration with Bristol Myers Squibb focused on the discovery and development of T-cell engager therapies for solid tumors. 1 ...

This article highlights how quality control microbiology is evolving into a proactive, integrated component of modern contamination control strategies across the biopharmaceutical lifecycle.

VP of operations and support at Kiteworks, with more than 20 years of experience in IT support and services. Since joining ...

Indirect data suggest oral semaglutide outperforms orforglipron on weight loss and tolerability, with patients also favoring its treatment profile.

The FDA approved the first generic dapagliflozin tablets, opening a competitive US market for pharma manufacturers and ...

Lilly licenses Insilico's AI drug discovery platform in a deal worth up to $2.75B, signaling a shift in how novel ...